The National Academy of Medicine today launched the Action Collaborative on Countering the U.S. Opioid Epidemic, a public-private partnership that will develop and disseminate evidence-based solutions to reduce opioid misuse and improve outcomes for individuals, families and communities affected by addiction. AHA is a member of the collaborative, chaired by NAM President Victor Dzau and co-chaired by Aspen Institute Vice President Ruth Katz, Health and Human Services Assistant Secretary for Health Brett Giroir and HCA Healthcare Chief Medical Officer Jonathan Perlin, former AHA chair. “The only viable approach to addressing the opioid misuse epidemic, the most pressing public health challenge of our time, is through multi-sector collaboration and a patient-centered approach,” said Giroir, senior advisor for mental health and opioid policy at HHS. “This collaborative brings the best from academia, industry, nonprofits and public service to identify opportunities and recommend bold action plans to yield results.” The collaborative will focus on issues such as appropriate prescribing practices, provider education and training, and opioid use disorder treatment. For an AHA toolkit and other resources to help hospitals and health systems tackle the opioid crisis, visit www.aha.org/opioidtoolkit.

Related News Articles

Headline
The Food and Drug Administration Sept. 10 released draft guidance on non-opioid treatments for treating chronic pain and reducing prescription opioid misuse.…
Headline
A Health Affairs study published Sept. 2 found that less than 40% of Medicare beneficiaries with opioid use disorder received standard care in alignment with…
Headline
The Food and Drug Administration July 31 announced that it is requiring safety label changes to all opioid pain medications to further emphasize and explain…
Headline
Overdose deaths in the U.S. fell 26.9% last year to 80,391, according to estimates from the Centers for Disease Control and Prevention. The agency reported…
Headline
The Food and Drug Administration Jan. 30 announced it approved Journavx (suzetrigine) oral tablets, a first-in-class non-opioid drug, to treat moderate to…
Headline
In this conversation, Vinnidhy Dave, D.O., hospice specialist and director of palliative medicine at Englewood Health Physician Network, and Lauren Savage,…